Lyon/Paris, 7 May 2013 – ERYTECH, a Lyon-based biopharmaceutical company that develops innovative therapies to combat acute leukaemia and other forms of cancer, today celebrated its successful listing on NYSE Euronext in Paris (NYX), raising €17.7 million – more than the figure initially targeted by the company.
ERYTECH was founded in 2004 to develop and introduce innovative therapies to fight acute leukaemia and other cancers, addressing medical needs for which current treatments are not suitable. The company's flagship product GRASPA® is currently being developed to treat acute lymphoblastic and myeloid leukaemia in Europe, and is part of a strategic partnership with Recordati-Orphan Europe that covers 38 European countries. GRASPA® also has major potential in the United States and for other indications such as solid tumours.
ERYTECH (ticker code: ERYP) was listed through the admission to trading of 4,015,618 existing shares and 1,524,334 new shares issued under a Global Offering. Given strong demand, the company opted for full exercise of the extension option and partial exercise of the over-allotment option, raising the total to €16.7 million, plus an additional €1 million representing shares subscribed through debt compensation.
The admission and issue price of ERYTECH shares was set at €11.60. Market capitalisation stood at around €64.3 million on the day of listing.
“We would like to extend a warm welcome to ERYTECH – our first listing on this scale from the Rhône-Alpes region, and on the French stock market since the beginning of the year,” said Marc Lefèvre, Head of European Business Development and Client Coverage, Listings Europe, at NYSE Euronext. “By raising €17.7 million – more than the amount initially targeted by the company – it was clearly a success. ERYTECH's listing testifies to renewed interest in the market by both institutional and individual investors.”
Gil Beyen, Chairman and CEO of ERYTECH, commented: “Our successful listing in compartment C of NYSE Euronext in Paris marks a new and important stage in our business development. It brings us both the financial resources and higher profile we need to accelerate our expansion in Europe and the United States, as well as in new cancer indications."